Bladder Cancer

During a Targeted Oncology case-based roundtable event, Arlene Siefker-Radtke discussed the second-line treatment options for a patient with urothelial carcinoma and the EV-301 trial of enfortumab vedotin.

Following the important information provided by the phase 3 VESPER trial, Jean Hoffman-Censits, Md said there are several noteworthy ongoing phase 3 neoadjuvant immunotherapy studies in bladder cancer.

Daniel P. Petrylak, MD, discusses the targeted therapies that have shown encouraging results in patients with metastatic urothelial cancer.

Sophia Kamran, MD, discusses the research supporting the use of trimodality therapy for patients with urothelial cancer.

Tracy Rose, MD, discussed the future of adjuvant and neoadjuvant therapy in muscle-invasive bladder cancer specifically using cisplatin-based regimens.

In recent years, the field of metastatic urothelial cancer has seen many new immunotherapy agents and targeted therapies that have improved patient outcomes.

Tracy L. Rose, MD, MPH, discusses ongoing research in bladder cancer that aims to add onto the standard of care and improve patient outcomes.

In an interview with Targeted Oncology, Sophia Kamran, MD, discussed the effectiveness of trimodality therapy as well as other novel therapeutics in patients with bladder cancer.

Patients with muscle invasive bladder cancer ineligible for cisplatin in cohort H of the phase 1b/2 EV-103 trial demonstrated promising antitumor activity when receiving neoadjuvant enfortumab vedotin.

The phase 2 BAYOU study failed to meet its primary end point of improvement in progression-free survival with olaparib plus durvalumab in patients with platinum-ineligible metastatic urothelial carcinoma.

Patients with checkpoint inhibitor–naïve metastatic urothelial cancer had promising anti-tumor activity when treated with sacituzumab govitecan and pembrolizumab in the second-line setting.

Mixed results were reported from the phase 2 ARIES clinical trial at the 2022 ASCO GU meeting.

Patients with urothelial cancer whose tumors overexpress c-Met may benefit from this unique combination.

An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.

Results from the combination of lenvatinib and pembrolizumab show similarity with the comparator in the phase 3 LEAP-011 study.

Much has changed in the understanding and treatment of urothelial cancer and questions are addressed in the updated ESMO clinical practice guidelines.

A novel gene therapy is being investigated for the treatment of Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, and the preliminary findings signal a high response rate with little toxicity.

Investigation of intravesical checkpoint-targeted therapy may warrant further investigation in patients with BCG-unresponsive bladder cancer.

According to Matthew Galsky, MD, results from the CheckMate-274 clinical trial support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial cancer after radical resection.

During a Targeted Oncology Case-Based Roundtable event, Shilpa Gupta, MD, discussed new options for late-line therapies including FGFR inhibitors in patients with bladder cancer.

Investigators reported meaningful pharmacodynamic and pharmacokinetic observations of BT5528 treatment, suggesting tumor penetration in a standard 3+ 3 dose-escalation trial.

A 66-year-old woman was referred by urology after evaluation for gross hematuria. After a clinical work-up, the patient was diagnosed with metastatic bladder cancer.

N-803 in combination with BCG has demonstrated disease-free survival benefit in patients with NMIBC. This meets the primary end point of the QUILT 3.032 study.

Results from the phase 4 MITO-BCG study show safety of sequential mitomycin with BCG for the treatment of high-risk muscle invasive bladder cancer.

In patients with metastatic or locally advanced urothelial carcinoma harboring FGFR alterations, erdafitinib (Balversa) in combination with cetrelimab displayed clinically meaningful responses.